SURI
Simplify Propel Opportunities ETF
Simplify Exchange Traded Funds
ETF
Expense ratio1
2.57%
Net assets2
$69.35M
Holdings2
43
Category
Allocation
2025 return3
25.11%

Investment objective & strategy

As of Oct. 31, 2025 · prospectus

Objective. Investment Objective: The Simplify Propel Opportunities ETF (the Fund or SURI) seeks long-term capital appreciation.

Strategy. Principal Investment Strategies: The Fund is an actively managed exchange-traded fund (ETF). The Funds investment adviser Simplify Asset Management Inc. (the Adviser) collaborates with the Funds sub-adviser, Propel Bio Management, LLC (the Sub-Adviser), to seek to achieve the Funds investment objective. The Fund concentrates its investments (i.e., invests more than 25% of its net assets) in the securities of issuers in the biotechnology, pharmaceuticals, healthcare technology, and life science tools and services industries. Each of these industries are commonly categorized within the healthcare sector because they share similar economic features and regulatory constraints. The Sub-Adviser employs an actively managed opportunistic multi-asset strategy that focuses on common stock, preferred stock, convertible bonds, structured notes, corporate notes and bonds, and ETFs that … Principal Investment Strategies: The Fund is an actively managed exchange-traded fund (ETF). The Funds investment adviser Simplify Asset Management Inc. (the Adviser) collaborates with the Funds sub-adviser, Propel Bio Management, LLC (the Sub-Adviser), to seek to achieve the Funds investment objective. The Fund concentrates its investments (i.e., invests more than 25% of its net assets) in the securities of issuers in the biotechnology, pharmaceuticals, healthcare technology, and life science tools and services industries. Each of these industries are commonly categorized within the healthcare sector because they share similar economic features and regulatory constraints. The Sub-Adviser employs an actively managed opportunistic multi-asset strategy that focuses on common stock, preferred stock, convertible bonds, structured notes, corporate notes and bonds, and ETFs that primarily invest in the preceding security types. The Adviser employs a derivatives strategy to partially protect or enhance Fund returns. The Sub-Adviser is responsible for security selection and the Adviser is responsible for trade execution, regulatory oversight of the Fund and the derivatives strategy. The Fund invests without restriction as to security currency, issuer capitalization (including micro-capitalization), or country and without restriction as to debt credit quality, maturity, structure, or issuer type. Lower quality corporate debt is commonly known as a junk bond. Junk bonds are generally rated lower than Baa3 by Moodys Investors Service, Inc. or lower than BBB- by Standard and Poors Ratings Group or lower than BBB- by Fitch Ratings, Inc. The Fund may invest in privately placed and restricted securities (including 144A bonds). The Fund is classified as a non-diversified fund under the Investment Company Act of 1940, as amended, which means that the Fund may invest a higher percentage of its assets in a fewer number of issuers than is permissible for a diversified Fund. Sub-Advisers Opportunistic Multi-Asset Strategy The Sub-Adviser selects securities that it believes present attractive investment opportunities, which may include securities that the Sub-Adviser believes are neglected and overlooked investments and present significant opportunities for capital appreciation. The Sub-Adviser uses fundamental, bottom-up analysis to identify securities that present attractive investment opportunities, which may include securities that the Sub-Adviser determines to be undervalued or present opportunities for growth. The Sub-Adviser selects debt or equity exposure based on its estimation of expected relative returns. The Sub-Adviser sells a security when it believes it is no longer undervalued or when more attractive investments are identified. Healthcare Sector Sub-Strategy The Sub-Adviser employs individuals who possess significant scientific, technical, operational, regulatory and commercial expertise to evaluate the science and prospects of healthcare sector companies as well as individuals with significant experience and expertise in identifying securities that present attractive investment opportunities, which may include securities that the Sub-Adviser determines to be undervalued or present opportunities for growth. Healthcare sector companies that the Fund typically includes in the portfolio are small to medium capitalization companies that may be in various stages of maturity. These may include early-stage companies which include those that routinely develop new products or services or are in the process of conducting clinical trials and may not yet be consistently profitable. The Sub-Advisers evaluation ranks the expected returns and risk profile of each potential investment based upon an evaluation of: (i) the scientific proposition of the issuer, (ii) the probability that the science will lead to a product or treatment, and (iii) projected profits from each successful product or treatment. Advisers Derivatives-Based Strategy The Fund may invest up to 20% of the Funds portfolio in derivatives, measured at market value. Such derivatives include equity, treasury, commodity, and currency futures (derivative contracts that obligate the buyer or seller to transact at a set price and predetermined time) and exchange-traded and over the counter (OTC) put and call options on equities, treasuries, commodities, and currencies or futures. The derivatives strategy is a form of leveraged investing. When the Fund purchases a call option, the Fund has the right, but not the obligation, to buy an asset at a specified price (strike price) within a specific time period. When the Fund purchases a put option, the Fund has the right, but not the obligation, to sell an asset at a specified price (strike price) within a specific time period. The Fund may invest in total return swaps such as swaps on high yield debt instruments or high yield indexes or equity indexes as reference assets. A total return swap is a swap agreement in which one party makes payments based on a set rate, either fixed or variable, while the other party makes payments based on the return of an underlying asset. These are regulatory primarily by the Commodity Futures Trading Commission or the Securities and Exchange Commission, depending on the underlying asset. The option overlay is a strategic, persistent exposure meant to partially hedge against market declines. If the market goes up, the Funds returns may outperform the market because the Adviser will sell or exercise the call options. If the market goes down, the Funds returns may fall less than the market because the Adviser will sell or exercise the put options. The Adviser selects derivatives based upon its evaluation of relative value, based on cost, strike price (price that the option can be bought or sold by the option holder) and maturity (the last date the option contract is valid) and exercises or closes the options typically based on maturity. The Adviser anticipates purchasing and selling its derivatives on a monthly, quarterly, and annual basis, depending upon the Funds rebalancing requirements and expiration dates. However, the Adviser may rebalance the Funds derivative portfolio on a more frequent basis for a number of reasons such as when market volatility renders the protection provided by the derivative strategy ineffective or a derivative position has appreciated to the point that it is prudent to decrease the Funds exposure and realize gains for the Funds shareholders. While the use of derivatives is intended to improve the Funds performance, there is no guarantee that it will do so. When using derivatives, the Fund is required to post collateral to assure its performance. The Fund will hold cash and cash-like instruments or high-quality short term fixed income securities (collectively, Collateral). The Collateral may consist of (1) U.S. Government securities, such as bills, notes and bonds issued by the U.S. Treasury; (2) money market funds, including affiliated money market ETFs; (3) fixed income ETFs; and/or (4) corporate debt securities, such as commercial paper and other short-term unsecured promissory notes issued by companies that are rated investment grade or of comparable quality. The Adviser considers an unrated security to be of comparable quality to a security rated investment grade if it believes it has a similar low risk of default. The Fund may continue to hold a position in an oil pipeline limited partnership, but this is not part of the Funds active investment strategy.

Top holdings

As of March 31, 2026 · N-PORT
SecurityTickerValue% of fund
U.S. Treasury Bills $64.45M 92.93%
Plains GP Holdings LP LTD PARTNER INT CL A NEW IN PAGP $30.89M 44.55%
ACHIEVE LIFE SCIENCES INC $3.48M 5.02%
PHATHOM PHARMACEUTICALS INC $2.92M 4.20%
DELCATH SYSTEMS $2.42M 3.49%
ABEONA THERAPEUTICS INC $2.24M 3.23%
CELLDEX THERAPEUTICS INC $2.19M 3.16%
MILESTONE PHARMACEUTICALS INC MIST $1.79M 2.58%
OCULIS HOLDING AG OCS $1.77M 2.56%
LEONABIO INC $1.53M 2.21%
View all holdings →

Allocation by sector

As of March 31, 2026 · N-PORT
View portfolio breakdown →

Portfolio moves

Dec 31, 2025 → Mar 31, 2026
Opened
20
Exited
9
Increased
2
Decreased
10
Unchanged
12

How many positions this fund opened, exited, grew, trimmed, or left unchanged between its two most recent N-PORT snapshots — net changes between point-in-time reports, not a trade log.

View portfolio moves →

Similar funds

Funds whose portfolios most overlap this one, by weight

Advisers

As of June 30, 2025 · N-CEN
FirmRole
Simplify Asset Management Inc. Adviser
Propel Bio Management, LLC Sub-adviser

Footnotes

  1. Expense ratio as of October 31, 2025, from the fund's prospectus.
  2. Net assets and holdings count as of March 31, 2026, from the fund's N-PORT filing.
  3. Total return for calendar year 2025, before tax and after fund expenses. Computed by compounding the twelve monthly total returns the fund reported in its SEC N-PORT filings for 2025 (the latest prospectus does not yet chart this year).

Machine-readable: JSON · Markdown. Programmatic access via the agent surface.